

# CURRICULUM VITAE

**Date of Revision: 04/10/2024**

**Name: Samaneh Asgari**

**Education:** *(Start with the first academic degree according to date; from past to present)*

1. *Bachelor in Science Pure Mathematics (2004-2007) - Mazandaran University, Babolsar, Iran*
2. *Master of statistics-Biostatistics (2008-2011)-University of Hasselt, Hasselt, Belgium*
3. *PhD of Epidemiology (2018-2021) - Shahid Beheshti University of medical sciences.*

**Career/Academic Appointments:** *(Academic positions should be listed by date from past to present )*

1. *Senior Researcher – (2011-2012) Shahid Beheshti hospital, Medical University of Babol, Iran*
2. *Research Consultant (2014-2018) Taleghani Hospital, Tehran, Iran*
3. *Research Consultant (2012-Dec 2022)-Prevention of Metabolic Disorders Research Center, Research Institute for Endocrine Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran*
4. *Assistant Professor – (Dec 2022-Current) Prevention of Metabolic Disorders Research Center, Research Institute for Endocrine Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran*

**Lectures, Courses, Web-based Education:** *(If you have presented or participated in any lecture, educational courses or web-based education, during the last 5 years mention their subject or title)*

*2020-2024: Research methods*

## PROFESSIONAL SERVICE

**Journal Service:** *(Membership in the editorial board, being a journal director, chief editor or the journal reviewing board or any related position)*

*2023-2024: Associated editor of cardiovascular Diabetology  
<https://cardiab.biomedcentral.com/about/editorial-board>*

## Bibliography:

### Peer-Reviewed Original Research:( *List of published articles according to Vancouver style, from past to present*)

#### Journal Articles

#### YEAR: 2023

1. External validation of the American prediction model for incident type 2 diabetes in the Iranian population. **Asgari S**, Khalili D, Azizi F, Hadaegh F. BMC Medical Research Methodology. 2023 Mar 29;23(1):77. **Q2** **IF: 2.00**
2. Prevalence and metabolic determinants of abnormal alanine aminotransferase: A cross-sectional study of Iranian adults, 2018–2022. **Asgari S**, Molavizadeh D, Tohidi M, Momenan AA, Azizi F, Hadaegh F. Journal of Clinical Laboratory Analysis. 2023 Jun;37(11-12):e24937. **Q2** **IF: 2.70**
3. Association of triglycerides to high-density lipoprotein cholesterol ratio to identify future prediabetes and type 2 diabetes mellitus: over one-decade follow-up in the Iranian population. Tohidi M, **Asgari S**, Chary A, Safiee S, Azizi F, Hadaegh F. Diabetology & Metabolic Syndrome. 2023 Dec;15(1):1-1. **Q2** **IF: 5.395**
4. The Trend of Risk for Cardiovascular Diseases During the Past Decade in Iran, Applying No-Lab and Lab-Based Prediction Models. Fahimfar N, Kohansal K, **Asgari S**, Ostovar A, Hadaegh F, Khalili D. Global Heart. 2023 Feb 10;18(1). **Q3** **IF: 3.218**

---

#### YEAR: 2022

5. Association between Wrist Circumference and Risk of Any Fracture in Adults: Findings from 15 Years of Follow-Up in the Tehran Lipid and Glucose Study. Tamehri Zadeh SS, Moazzeni SS, **Asgari S**, Mirbolouk M, Azizi F, Hadaegh F. Journal of Clinical Medicine. 2022 Nov 29;11(23):7048. **Q2** **IF: 4.964**
6. The association between low-density and non-high-density lipoprotein cholesterol with incident cardiovascular disease among low-risk Iranians during 2 decades follow-up. Tohidi M, **Asgari S**, Chary A, Azizi F, Hadaegh F. Clinical Biochemistry. 2022 Nov 1;109:28-36. **Q2** **IF: 3.625**
7. Differences in the impact of impaired glucose status on clinical outcomes in younger and older adults: Over a decade of follow-up in the Tehran lipid and glucose study. **Asgari S**, Masrouri S, Khalili D, Azizi F, Hadaegh F. Frontiers in Cardiovascular Medicine. 2022 Oct 31:2995. **Q2** **IF: 5.848**
8. Association of ideal cardiovascular health metrics and incident type 2 diabetes mellitus among an urban population of Iran: One decade follow up in the Tehran Lipid and Glucose Study. **Asgari S**, Masrouri S, Hosseinpour-Niazi S, Moslehi N, Azizi F, Hadaegh F. Journal of Diabetes Investigation. 2022 Oct;13(10):1711-22. **Q3** **IF: 3.681**
9. Health system performance in Iran: a systematic analysis for the Global Burden of Disease Study 2019. Farzadfar F, Naghavi M, Sepanlou SG, Moghaddam SS, Dangel WJ, Weaver ND, Aminorroaya A, Azadnajafabad S, Koolaji S, Mohammadi E, Rezaei N. The Lancet. 2022 Apr 23;399(10335):1625-45. **Q1** **IF: 202.731**
10. The Association of Ideal Cardiovascular Health Metrics and Incident Type 2 Diabetes Mellitus Among an urban population of Iran: a decade follow-up in Tehran Lipid and Glucose Study. **Asgari S**, Masrouri S, Hosseinpour S, Moslehi N, Azizi F, Hadaegh F. Journal of Diabetes Investigation. 2022 May 19. **Q1** **IF: 4.23**
11. xsGastrointestinal symptoms are associated with a lower risk of hospitalization and mortality and Outcomes in COVID-19. Delavari A, **Asgari S**, Alimohamadi Y, Vosoogh-Moghaddam A, Sadeghi A, Shahrousvand S, Zakeri A, Moradzadeh R, Akbarpour S. BMC gastroenterology. 2022 Dec;22(1):1-0. **Q3** **IF: 3.065**
12. Diabetes mortality and trends before 25 years of age: an analysis of the Global Burden of Disease Study 2019. Cousin E, Duncan BB, Stein C, Ong KL, Vos T, Abbafati C, Abbasi-Kangevari M, Abdelmasseh M, Abdoli A, Abd-Rabu R, Abolhassani H. The Lancet Diabetes & Endocrinology. 2022 Mar 1;10(3):177-92. **Q1** **IF: 32.069**
13. Letter to the Editor Regarding “Nationwide Prevalence of Diabetes and Prediabetes and Associated Risk Factors Among Iranian Adults: Analysis of Data from PERSIAN Cohort Study”. **Asgari S**, Khalili D, Mehrabi Y, Hadaegh F. Diabetes Therapy. 2021 Dec 3:1-3. **Q2**

**IF:2.945**

14. Incidence and risk factors of severe non-proliferative/proliferative diabetic retinopathy: More than a decade follow up in the Tehran Lipids and Glucose Study. Sardarina M, **Asgari S**, Hizomi Arani R, Eskandari F, Azizi F, Khalili D, Hadaegh F. Journal of Diabetes Investigation. 2021 Aug 17. **Q1 IF:4.232**

---

**YEAR: 2021**

15. The association of parity/live birth number with incident type 2 diabetes among women: over 15 years of follow-up in The Tehran Lipid and Glucose Study. Moazzeni SS, Hizomi Arani R, **Asgari S**, Azizi F, Hadaegh F. BMC women's health. 2021 Dec;21(1):1-9. **Q2 IF:2.809**
16. Dynamic prediction models improved the risk classification of type 2 diabetes compared with classical static models. **Asgari S**, Khalili D, Zayeri F, Azizi F, Hadaegh F. Journal of Clinical Epidemiology. 2021 Dec 1;140:33-43. **Q1 IF:6.437**
17. Live birth/parity number and the risk of incident hypertension among parous women during over 13 years of follow-up. Moazzeni SS, **Asgari S**, Azizi F, Hadaegh F. The Journal of Clinical Hypertension. 2021 Oct 17. **Q2 IF:3.738**
18. Number of parity/live birth (s) and cardiovascular disease among Iranian women and men: results of over 15 years of follow-up. BMC Pregnancy and Childbirth. Moazzeni SS, Toreyhi H, **Asgari S**, Azizi F, Tehrani FR, Hadaegh F. 2021 Dec;21(1):1-1. **Q2 IF:3.007**
19. Prediction Models for Type 2 Diabetes Risk in the General Population: A Systematic Review of Observational Studies. **Asgari S**, Khalili D, Hosseinpanah F, Hadaegh F. International Journal of Endocrinology and Metabolism. 2021 Dec 31. **Q3**
20. Macrosomia is a risk factor for incident maternal chronic kidney disease. BMC Pregnancy and Childbirth. Vahidi M, **Asgari S**, Tohidi M, Azizi F, Hadaegh F. 2021 Dec;21(1):1-2. **Q2 IF:3.007**
21. The risk and added values of the atherosclerotic cardiovascular risk enhancers on prediction of cardiovascular events: Tehran lipid and glucose study. Hadaegh F, **Asgari S**, Moosaie F, Orangi M, Sarvghadi F, Khalili D, Azizi F. Journal of Translational Medicine. 2021 Dec;19(1):1-4. **Q1 IF:5.531**
22. Sudden cardiac death among Iranian population: a two decades follow-up of Tehran lipid and glucose study. Toreyhi H, **Asgari S**, Khalili D, Pishgahi M, Azizi F, Hadaegh F. Scientific reports. 2021 Aug 3;11(1):1-0. **Q1 IF:4.379**
23. Anthropometric indices and the risk of incident sudden cardiac death among adults with and without diabetes: over 15 years of follow-up in The Tehran Lipid and Glucose Study. Moazzeni SS, Tamehri Zadeh SS, **Asgari S**, Azizi F, Hadaegh F. Diabetology & metabolic syndrome. 2021 Dec;13(1):1-2. **Q2 IF:3.32**
24. Long term prognostic implication of newly detected abnormal glucose tolerance among patients with stable cardiovascular disease: a population-based cohort study Kabootari M, **Asgari S**, Ghavam SM, Abdi H, Azizi F, Hadaegh F.. Journal of translational medicine. 2021 Dec;19(1):1-2. **Q1 IF:5.531**
25. The Role of Metabolic Syndrome and its Components in Incident Fracture: A 15-year follow-up among the Iranian Population. Amouzegar A, **Asgari S**, Azizi F, Momenan AA, Bozorgmanesh M, Hadaegh F. The Journal of Clinical Endocrinology & Metabolism. 2021 May;106(5):e1968-83. **Q1 IF:5.958**
26. Sex-specific incidence rates and risk factors for fracture: A 16-year follow-up from the Tehran lipid and glucose study. Hadaegh F, **Asgari S**, Toreyhi H, Eskandari F, Fahimfar N, Bozorgmanesh M, Hosseinpanah F, Azizi F. Bone. 2021 May 1;146:115869. **Q1 IF:4.398**
27. National trends in cardiovascular health metrics among Iranian adults using results of three cross-sectional STEPwise approaches to surveillance surveys. Rahmani F, **Asgari S**,

Khalili D, Moeini AS, Tohidi M, Azizi F, Hadaegh F. Scientific Reports. 2021 Jan 8;11(1):1-1.

**Q1** **IF:4.379**

28. Number of parity/live birth (s) and cardiovascular disease among Iranian women and men: results of over 15 years of follow-up. BMC Pregnancy and Childbirth. Moazzeni SS, Toreyhi H, **Asgari S**, Azizi F, Tehrani FR, Hadaegh F. 2021 Dec;21(1):1-1. **Q2** **IF:3.007**
29. The association of parity/live birth number with incident type 2 diabetes among women: over 15 years of follow-up in The Tehran Lipid and Glucose Study. Moazzeni SS, Hizomi Arani R, **Asgari S**, Azizi F, Hadaegh F. BMC women's health. 2021 Dec;21(1):1-9. **Q2** **IF:2.809**
30. Mapping routine measles vaccination in low-and middle-income countries. Local Burden of Disease Vaccine Coverage Collaborators. Nature. 2021;589(7842):415. **Q1** **IF:49.962**

---

## YEAR: 2020

31. The external validity and performance of the no-laboratory American Diabetes Association screening tool for identifying undiagnosed type 2 diabetes among the Iranian population. **Asgari S**, Lotfaliany M, Fahimfar N, Hadaegh F, Azizi F, Khalili D. Primary Care Diabetes. 2020 Jun 7. **Q2** **IF:2.052**
32. Five insights from the Global Burden of Disease Study 2019. Abbafati, C., Machado, D.B., Cislighi, B., ..., Zheleva, B., Zhu, C. The Lancet, 2020, 396(10258), pp. 1135–1159. **Q1** **IF:60.392**
33. Global burden of 87 risk factors in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. Abbafati, C., Machado, D.B., Cislighi, B., ..., Zheleva, B., Zhu, C. The Lancet, 2020, 396(10258), pp. 1223–1249. **Q1** **IF:60.392**
34. Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. Abbafati, C., Machado, D.B., Cislighi, B., ..., Zheleva, B., Zhu, C. The Lancet, 2020, 396(10258), pp. 1204–1222. **Q1** **IF:60.392**
35. Global age-sex-specific fertility, mortality, healthy life expectancy (HALE), and population estimates in 204 countries and territories, 1950–2019: a comprehensive demographic analysis for the Global Burden of Disease Study 2019. Abbafati, C., Machado, D.B., Cislighi, B., ..., Zheleva, B., Zhu, C. The Lancet, 2020, 396(10258), pp. 1160–1203. **Q1** **IF:60.392**
36. External validation of the European risk assessment tool for chronic cardio-metabolic disorders in a Middle Eastern population. **Asgari, S.**, Moosaie, F., Khalili, D., Azizi, F., Hadaegh, F. Journal of Translational Medicine, 2020, 18(1), 267. **Q1** **IF: 4.197**
37. Mapping local patterns of childhood overweight and wasting in low- and middle-income countries between 2000 and 2017. Kinyoki, D.K., Ross, J.M., Lazzar-Atwood, A., ...Afshin, A., Hay, S.I. Nature Medicine, 2020, 26(5), pp. 750–759. **Q1** **IF:36.13**
38. Sex-Specific Incidence Rates and Risk Factors for Hypertension During 13 Years of Follow-up: The Tehran Lipid and Glucose Study. Global Heart. **Asgari S**, Moazzeni SS, Azizi F, Abdi H, Khalili D, Hakemi MS, Hadaegh F.. 2020;15(1). **Q2**; **IF:3**
39. All-cancer incidence in Tehranian adults: more than a decade of follow-up—results from the Tehran Lipid and Glucose Study. Hadaegh F, **Asgari S (co-first author)**, Hashemi P, Baghbani-Oskouei A, Eskandari F, Azizi F, Tohidi M. Public Health. 2020 Apr 1;181:189-95. **Year: 2018. Q**

---

## YEAR: 2019

40. Status of Hypertension in Tehran: Potential impact of the ACC/AHA 2017 and JNC7 Guidelines, 2012-2015. **Asgari S**, Khaloo P, Khalili D, Azizi F, Hadaegh F. Sci Rep. 2019 Apr 23;9(1):6382. doi: 10.1038/s41598-019-42809-3. **Q1** **IF: 3.998**
41. Body mass index trajectories from adolescent to young adult for incident high blood pressure and high plasma glucose. Ahanchi NS, Ramezankhani A, Munthali RJ, **Asgari S**, Azizi F, Hadaegh F. PLoS One. 2019 May 1;14(5):e0213828. doi: 10.1371/journal.pone.0213828. eCollection 2019. **Q1** **IF: 2.74**
42. Non-invasive Risk Prediction Models in Identifying Undiagnosed Type 2 Diabetes or Predicting Future Incident Cases in the Iranian Population. Lotfaliany M, Hadaegh F, **Asgari S**, Mansournia MA, Azizi F,

Oldenburg B, Khalili D. Arch Iran Med. 2019 Mar 1;22(3):116-124. **Q1** IF: 0.996

43. Long-Term Effectiveness of a Lifestyle Intervention: A Pragmatic Community Trial to Prevent Metabolic Syndrome. DavoodKhalili, **SamanehAsgari**, MojtabaLotfaliany, NedaZafari, FarzadHadaegh, Amir-AbbasMomenan, ArminNowroozpoor, FiroozehHosseini-Esfahani, ParvinMirmiran, ParisaAmiri, FereidounAzizi. American Journal of Preventive Medicine. Volume 56, Issue 3, March 2019, Pages 437-446. doi:10.1016/j.amepre.2018.10.029. **Q1** IF:4.527

---

## YEAR: 2018

44. The Burden of Statin Therapy based on ACC/AHA and NCEP ATP-III Guidelines: An Iranian Survey of Non-Communicable Diseases Risk Factors. **Asgari S**, Abdi H, Hezaveh AM, Moghisi A, Etemad K, Beni HR, Khalili D. Sci Rep. 2018 Mar 21;8(1):4928. doi: 10.1038/s41598-018-23364-9. **Q1** IF: 3.998
45. Serum alkaline phosphatase and the risk of coronary heart disease, stroke and all-cause mortality: Tehran Lipid and Glucose Study. Kabootari M, Raei MR, Akbarpour S, **Asgari S**, Azizi F, Hadaegh F. BMJ Open. 2018 Nov 25;8(11):e023735. doi: 10.1136/bmjopen-2018-023735. **Q1** IF:2.496
46. Blood pressure components and incident cardiovascular disease and mortality events among Iranian adults with chronic kidney disease during over a decade long follow-up: a prospective cohort study. Hashemi A, Nourbakhsh S, **Asgari S**, Mirbolouk M, Azizi F, Hadaegh F. J Transl Med. 2018 Aug 15;16(1):230. doi: 10.1186/s12967-018-1603-7. **Q1** IF: 4.197
47. Direct and indirect effects of central and general adiposity on cardiovascular diseases: The Tehran Lipid and Glucose Study. Bakhtiyari M, Schmidt N, Hadaegh F, Khalili D, Mansournia N, **Asgari S**, Mansournia MA. Eur J Prev Cardiol. 2018 Jan 1:2047487318780030. doi: 10.1177/2047487318780030. **Q1** IF:5.64
48. World Bank Income Group, Health Expenditure or Cardiometabolic Risk Factors? A Further Explanation of the Wide Gap in Cardiometabolic Mortality Between Worldwide Countries: An Ecological Study. Lotfaliany M, Akbarpour S, Zafari N, Mansournia MA, **Asgari S**, Azizi F, Hadaegh F, Khalili D. Int J Endocrinol Metab. 2018 Jul 10;16(3):e59946. doi: 10.5812/ijem.59946. eCollection 2018 Jul. **Q3**
49. Clinical outcome according to spasm type of single coronary artery provoked by intracoronary ergonovine tests in patients without significant organic stenosis: Methodological and statistical issues. **Asgari S**. Int J Cardiol. 2018 Jun 1;260:19. doi: 10.1016/j.ijcard.2017.12.108. No abstract available. **Q1** IF: 3.471
50. Association between duration of oral contraceptive use and risk of hypertension: A meta-analysis, methodological and statistical issues. **Asgari S**. J Clin Hypertens (Greenwich). 2018 Mar;20(3):613. doi: 10.1111/jch.13208. Epub 2018 Feb 15. No abstract available. **Q2** IF: 2.719
51. Different Weight Histories and Risk of Incident Coronary Heart Disease and Stroke: Tehran Lipid and Glucose Study. Kabootari M, **Asgari S**, Mansournia MA, Khalili D, Valizadeh M, Azizi F, Hadaegh F. J Am Heart Assoc. 2018 Feb 10;7(4). pii: e006924. doi: 10.1161/JAHA.117.006924. **Q1** IF:4.45
52. Serum Lipids During 20 Years in the Tehran Lipid and Glucose Study: Prevalence, Trends and Impact on Non-Communicable Diseases. Baghbani-Oskouei A, Tohidi M, **Asgari S**, Ramezankhani A, Azizi F, Hadaegh F. Int J Endocrinol Metab. 2018 Oct 16;16(4 Suppl):e84750. doi: 10.5812/ijem.84750. eCollection 2018 Oct. Review. **Q3**
53. New modified Friedewald formulae for estimating low-density lipoprotein cholesterol according to triglyceride levels: extraction and validation. Ghasemi A, **Asgari S**, Hadaegh F, Kheirandish M, Azimzadeh I, Azizi F, Tohidi M. Endocrine. 2018 Nov;62(2):404-411. doi: 10.1007/s12020-018-1685-2. Epub 2018 Jul 24. **Q1** IF:3.235
54. Outcomes of a Longitudinal Population-based Cohort Study and Pragmatic Community Trial: Findings from 20 Years of the Tehran Lipid and Glucose Study. Khalili D, Azizi F, **Asgari S**, Zadeh-Vakili A, Momenan AA, Ghanbarian A, Eskandari F, Sheikholeslami F, Hadaegh F. Int J Endocrinol Metab. 2018 Oct 13;16(4 Suppl):e84748. doi: 10.5812/ijem.84748. eCollection 2018 Oct. Review. **Q3**

---

## YEAR: 2017

55. Impact of Hypertension versus Diabetes on Cardiovascular and All-cause Mortality in Iranian Older Adults: Results of 14 Years of Follow-up. Zafari N, **Asgari S**, Lotfaliany M, Hadaegh A, Azizi F, Hadaegh F. Sci Rep. 2017 Oct 27;7(1):14220. doi: 10.1038/s41598-017-14631-2. **Q1** IF: 3.998

56. Predictors of early adulthood hypertension during adolescence: a population-based cohort study. Kalantari S, Khalili D, **Asgari S**, Fahimfar N, Hadaegh F, Tohidi M, Azizi F. *BMC Public Health*. 2017 Nov 28;17(1):915. doi: 10.1186/s12889-017-4922-3. **Q1 IF:1.198**
57. The association between changes in blood pressure components and incident cardiovascular diseases. Parizadeh D, Ghahvehchian H, **Asgari S**, Momenan AA, Azizi F, Hadaegh F. *Blood Press*. 2017 Jul 14:1-9. doi: 10.1080/08037051.2017.1353882. **Q2 IF: 2.169**
58. Letter to the editor regarding Yanhui Dong et al: "National Blood Pressure Reference for Chinese Han Children and Adolescents Aged 7 to 17 Years". **Samaneh Asgari**. *Hypertension*. 2017;70:897-906 Originally published September 18, 2017. **Q1 IF: 7.017**
59. Determining the Factors Associated with Cardiovascular Disease Recurrence: Tehran Lipid and Glucose Study. Taravatmanesh S, Khalili D, Khodakarim S, **Asgari S**, Hadaegh F, Azizi F, Sabour S. *J Tehran Heart Cent*. 2017 Jul;12(3):107-113. Review. **Q4**

---

## YEAR: 2016

60. Obesity Paradox and Recurrent Coronary Heart Disease in a Population-Based Study: Tehran Lipid and Glucose Study. **Asgari S**, Barzin M, Hosseinpanah F, Hadaegh F, Azizi F, Khalili D. *Int J Endocrinol Metab*. 2016 Apr 16;14(2):e37018. eCollection 2016 Apr 16. **Q3**
61. Divergent pathway of lipid profile components for cardiovascular disease and mortality events: Results of over a decade follow-up among Iranian population. Ghasemzadeh Z, Abdi H, **Asgari S**, Tohidi M, Khalili D, Valizadeh M, Moeini S, Eidkhani V, Azizi F, Hadaegh F. *Nutr Metab (Lond)*. 2016 Jun 24;13:43. doi: 10.1186/s12986-016-0102-1. eCollection 2016. **Q1 IF:3.455**
62. Incidence and risk factors of isolated systolic and diastolic hypertension: a 10 year follow-up of the Tehran Lipids and Glucose Study. **Asgari S**, Khalili D, Mehrabi Y, Kazempour-Ardebili S, Azizi F, Hadaegh F. *Blood Press*. 2016 Jun;25(3):177-83. doi: 10.3109/08037051.2015.1116221. Epub 2015 Dec 8. **Q2 IF: 2.169**
63. Added value of total serum nitrate/nitrite for prediction of cardiovascular disease in Middle East caucasian residents in Tehran. Hadaegh F, **Asgari S**, Bozorgmanesh M, Jeddi S, Azizi F, Ghasemi A. *Nitric Oxide*. 2016 Apr 1;54:60-6. doi: 10.1016/j.niox.2016.02.004. Epub 2016 Feb 23. **Q2 IF: 3.311**
64. Change in fasting plasma glucose and incident type 2 diabetes mellitus: results from a prospective cohort study. Mozaffary A, **Asgari S (co-first author)**, Tohidi M, Kazempour-Ardebili S, Azizi F, Hadaegh F. *BMJ Open*. 2016 May 23;6(5):e010889. doi: 10.1136/bmjopen-2015-010889. PMID: 27217283 Free PMC Article (Mozaffary A and Asgari S are first co-author). **Q1 IF: 2.496**
65. Expression of estrogen and progesterone receptors in papillary thyroid carcinoma. Jalali-Nadoushan MR, Amirtouri R, Davati A, **Asgari S**, Siadati S. *Caspian journal of internal medicine*. 2016;7(3):183.

---

## YEAR: 2015

66. Sex-specific relations between fasting insulin, insulin resistance and incident hypertension: 8.9 years follow-up in a Middle-Eastern population. Arshi B, Tohidi M, Derakhshan A, **Asgari S**, Azizi F, Hadaegh F. *Journal of human hypertension*. 2015 Apr;29(4):260-7. **Q2 IF:2.433**
  67. Different obesity phenotypes and incident cardiovascular disease and mortality events in elderly Iranians: Tehran lipid and glucose study. Mirbolouk M, **Asgari S**, Sheikholeslami F, Mirbolouk F, Azizi F, Hadaegh F. *Geriatr Gerontol Int*. 2015 Apr;15(4):449-56. doi: 10.1111/ggi.12295. Epub 2014 Apr 21. **Q2 IF:2.022**
  68. A new approach to test validity and clinical usefulness of the 2013 ACC/AHA guideline on statin therapy: A population-based study. Khalili D, **Asgari S**, Hadaegh F, Steyerberg EW, Rahimi K, Fahimfar N, Azizi F. *Int J Cardiol*. 2015 Apr 1;184:587-94. doi: 10.1016/j.ijcard.2015.03.067. Epub 2015 Mar 5. **Q1 IF:3.471**
  69. The burden of statin therapy in urban population of Iran based on new ACC/AHA guideline. **Asgari, S.**, Khalili, D., Azizi, F., Eskandari, F., Sarbazi, N. and Hadaegh, F., 2015. *Tehran University Medical Journal TUMS Publications*,72(12), pp.814-822.
-



## YEAR: 2014

70. Secular trends in serum lipid levels of a Middle Eastern adult population; 10 years follow up in Tehran lipid and glucose study. Kheirandish M, **Asgari S**, Lotfaliany M, Bozorgmanesh M, Saadat N, Tohidi M, Azizi F, Hadaegh F. *Lipids Health Dis.* 2014 Jan 23;13:20. doi: 10.1186/1476-511X-13-20. **Q2** **IF:2.906**
- 

## YEAR: 2013

71. Comparison of stool antigen test with gastric biopsy for the detection of Helicobacter Pylori infection. Sharbatdaran M, Kashifard M, Shefaee S, Siadati S, Jahed B, **Asgari S**. *Pak J Med Sci.* 2013 Jan;29(1):68-71. doi: 10.12669/pjms.291.2865. **Q2** **IF:0.834**
72. Concordance rate between fine needle aspiration biopsy and core needle biopsy in breast lesions. Ghaemian N, Siadati S, Nikbakhsh N, Mirzapour M, Askari H, **Asgari S**. *Iranian Journal of Pathology.* 2013 Oct 1;8(4):241-6. **Q3**
73. Seroprevalence of Varricella Zoster Antibodies among Pregnant Women in Babol, Northern Iran. Masomeh Bayani, Sepideh Siadati, Seddigeh Esmaeilzadeh, **Samaneh Asgari**, Saeed Salmani . *Iranian Journal of Pathology* (2013) 8 (3), 171 – 177. **Q3**
74. Effect of Growth Indices on Malnutrition in Infants from Health Medical Centers of Babol, Iran 2011-2012. **Zabihi** , M. Rafati Rahimzadeh, S.R. Jafarian Amiri, P. Sajadi, S. Asgari . *J Babol Univ Med Sci*; 15(6); Nov 2013. **Q3**
75. Electronic database annual report on abdominal wall hernias, 2010-2011, Shahid Beheshti University Hospital, Babol, Iran. Ali Asghar Darzi, Seyed Reza Hashemi, Asgari Noorbaran, Abdol Rahim Gholizadeh Pasha, Seyed Reza Modares , Novin Nikbakhsh, Bahman Farhangi , Emaduddin Moudi, Soraya Khafri, Mohadeseh Mirzapour and Samaneh Asgari. *World Applied Sciences Journal* 21 (7): 1084-1088, 2013.
- 

## YEAR: 2012

76. Years of Potential Life Lost due to unintentional drowning mortality in Mazandaran province. Akbarpour Samaneh, **Asgari Samaneh** (corresponding Author), Soori H, Khosravi A, GhasempourinKh. *World Applied Sciences Journal* 20 (10): 1433-1438, 2012.
77. BLADDER CANCER RISK FACTORS: STUDY OF 238 CASES IN NORTH OF IRAN, BABOL Hamid S, Arsalan A, **Samaneh A**, Mahaddeseh M.. *International Journal of Urology.* **2012** Aug;19.
-